Pandemic Timeline

SARS-CoV-2 Timeline

SARS-CoV-2 Timeline

November 28 2020

Ivermectin: risk of death, 99.4% lower

– Ivermectin: risk of death, 99.4% lower, RR 0.006, p = 0.08, treatment 0 of 69 (0.0%), control 150 of 3,062 (4.9%), continuity correction due to zero event. risk of COVID-19 case, 55.1% lower, RR 0.45, p = 0.01, treatment 7 of 69 (10.1%), control 692 of 3,062 (22.6%). Bernigaud et al., 11/28/2020, retrospective, France, Europe, peer-reviewed, 12 authors, dosage 200μg/kg days 1, 8, 15, 400μg/kg days 1, 8, 15, two different dosages.

December 1 2020

1,000 Alberta schools report at least one case of the virus

Through December, more than 1,000 Alberta schools report at least one case of the virus, including more than 300 where in-school transmission was suspected, according to the Calgary Herald.

December 2 2020

Ivermectin: risk of unresolved symptoms, 85.0% lower

Ivermectin: risk of unresolved symptoms, 85.0% lower, RR 0.15, p = 0.09, treatment 0 of 17 (0.0%), control 3 of 19 (15.8%), continuity correction due to zero event, day 7 fever ivermectin.
Ahmed et al., 12/2/2020, Double Blind Randomized Controlled Trial, Bangladesh, South Asia, peer-reviewed, mean age 42.0, 15 authors, dosage 12mg days 1-5, ivermectin + doxycycline group took only a single dose of ivermectin.

December 8 2020

Alberta introduces strict lockdowns for second wave

Kenney introduces strict lockdown measures to combat the rapidly growing second wave. The lockdown includes a ban on indoor and outdoor gatherings, the shuttering of non-essential businesses, and mandatory mask mandates. By mid-December, Alberta has the highest rate of active COVID-19 cases in the country.

December 10 2020

An FDA advisory panel endorses the first COVID-19 vaccine.

An FDA advisory panel endorses the first COVID-19 vaccine. The application for the Pfizer and BioNTech’s vaccine is heard in a public, day-long meeting; voting 17-4, with 1 abstention, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) decides the benefits of the vaccine outweigh the risks for those 16 and older.

December 14 2020

HCQ lowers risk of death by 33%

Retrospective 1,214 hospitalized patients in Pakistan, 77 HCQ patients, showing 33% lower mortality with HCQ, multivariate Cox HR 0.67, p = 0.34.
risk of death, 33.3% lower, RR 0.67, p = 0.34, treatment 77, control 1137, multivariate Cox.
Naseem et al., 12/14/2020, retrospective, Pakistan, South Asia, preprint, 5 authors.

December 15 2020

Ivermectin: risk of COVID-19 case, 90.6% lower

Ivermectin: risk of COVID-19 case, 90.6% lower, RR 0.09, p < 0.001, treatment 4 of 58 (6.9%), control 44 of 60 (73.3%).
Alam et al., 12/15/2020, prospective, Bangladesh, South Asia, peer-reviewed, 13 authors, dosage 12mg monthly.

December 17 2020

FDA Panel Backs Moderna COVID-19 Vaccine

A week after hearing the application for the country’s first COVID-19 vaccine, the same FDA advisory panel meets and agrees that a second vaccine, from Moderna, will benefit individuals 18 years and older. The vote is 20-0, with 1 abstention. The Moderna vaccine is given 28 days apart; the Pfizer-BioNtech one, 21 days apart.

December 19 2020

Pfizer vaccine doses arrived in Israel

The first Pfizer vaccine doses arrived in Israel on December 9, 2020, and vaccinations began on December 19, 2020.

December 21 2020

New COVID-19 Variant Circling the UK

The UK announces that a new strain of the virus that causes COVID-19, B.1.1.7, is spreading across the country. The novel variant is more contagious, but does not appear to be more lethal or lead to more severe disease.

December 27 2020

Vaccines started in Spain

The first vaccines started being administered to the Spanish population.

December 28 2020

Novavax Starts Phase 3 Trial of COVID-19 Vaccine

Novavax begins a phase 3 clinical trial, PREVENT-19, for its investigational COVID-19 vaccine, NVX-CoV2373, in 30,000 volunteers in Mexico and the United States.

December 28 2020

Medical ivermectin kits

medical ivermectin kits have been provided to positive mild to moderate symptomatic patients, After one month, 83,000 medical kits delivered. Reductions in excess deaths (30 days after peak deaths) maximal, 74% medium, 53% minimal, 25%

December 30 2020

UK Approves Emergency Authorization for the AZ and Oxford COVID-19 Vaccine

As UK cases surge, regulators clear a vaccine from AstraZeneca and Oxford, AZD1222, for individuals 18 years and older.

December 31 2020

Politics invading scientific research

Dec. 31, 2020 – Characteristics and outcomes of COVID-19 patients admitted to a regional health system in the southeast
Retrospective 161 hospitalized patients in the USA showing non-statistically significant unadjusted increased mortality with HCQ. Confounding by indication is likely.
Time varying confounding is likely. HCQ became controversial and was suspended towards the end of the period studied, therefore HCQ use was likely more frequent toward the beginning of the study period, a time when overall treatment protocols were significantly worse.
risk of death, 79.3% higher, RR 1.79, p = 0.10, treatment 17 of 65 (26.2%), control 14 of 96 (14.6%).
Texeira et al., 12/31/2020, retrospective, USA, North America, peer-reviewed, 6 authors.